Squarepoint
INDV icon

Squarepoint’s Indivior Pharmaceuticals INDV Stock Holding History

Squarepoint’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$413K Buy
+10,058
New +$365K ﹤0.01% 3572
2025
Q4 		– Sell
-10,029
Closed -$242K – 4551
2025
Q3 		$242K Buy
+10,029
New +$210K ﹤0.01% 3816
2025
Q2 		– Sell
-201,577
Closed -$1.92M – 4750
2025
Q1 		$1.92M Buy
+201,577
New +$2.12M ﹤0.01% 2125

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Squarepoint's INDV Position: Q2 2026 in Review

Squarepoint opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 10,058 shares worth $413K. The stake represents ﹤0.01% of the portfolio and ranks #3572 among its holdings. This is a return to the name: Squarepoint previously reported a position in INDV as recently as Q3 2025.

Squarepoint first reported a position in INDV in Q1 2025 and has held it in 3 quarters since. The position peaked at $1.92M in Q1 2025. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Squarepoint held 10,058 shares of Indivior Pharmaceuticals worth $413K as of Q2 2026.
  • Indivior Pharmaceuticals was a new Squarepoint position in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3572 holding.
  • Squarepoint first reported a position in Indivior Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Squarepoint's Indivior Pharmaceuticals position peaked at $1.92M in Q1 2025.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.